An Analysis of the Facts and Circumstances of the Worobey Science Perspective Paper Suggests it Makes No Contribution to the Investigation of the Origin of SARS-CoV-2


  • If it was believed that the pandemic began in December 2019 then the epidemiology of patients from December 2019 would be helpful in identifying the origin of the infection. If the December cases are appearing weeks or months after the Index Case, then the December epidemiology is less valuable.
  • Nonetheless, the earliest data on the relationship to the Huanan market, which has never been refuted, documents three of the first four cases had no relationship to the market.
  • Abundant evidence exists that the first patient with COVID-19 was in Wuhan, China and was infected sometime between the end of September 2019 and late November 2019. This includes Worobey’s own prior work.
  • We do not know who that first patient is, where they lived, their market association, etc.
  • By early December the ‘spacio-temporal’ signal from the unknown ‘Index Patient’ was lost through repeated human-to-human transmission. Therefore, classifying or reclassifying one of the three early patients with no exposure to the market to a later infection date does not change the probative value of those early cases, which is minimal.
  • The uncritical media response to this paper suggests a desire to close the debate on the origin of SARS-CoV-2 and to undermine the extensive evidence which is most consistent with a non-spillover event as the origin.

Steven Quay is the founder of Seattle-based Atossa Therapeutics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions.

He received his M.D. and Ph.D. from The University of Michigan, was a postdoctoral fellow at MIT with Nobel Laureate H. Gobind Khorana, a resident at the Harvard-MGH Hospital, and was on the faculty of Stanford University School of Medicine. His contributions to medicine have been cited over 9,600 times. He has founded six startups, invented seven FDA-approved pharmaceuticals, and holds 87 US patents. Over 80 million people have benefited from the medicines he invented.

His current passion is the prevention of the two million yearly breast cancer cases worldwide.

Related Content

In a recent conversation on The Vince Coglianese Show, Dr. Steven Quay shares his thoughts on various aspects of the COVID-19 pandemic, shedding light on critical issues ranging from the origins of the virus to the trust deficit in the medical community.

The recent House Committee testimony has stirred up discussions regarding public health, vaccination, and trust in government agencies. Dr. Quay breaks down Dr. Fuaci's testimony with Rich Valdés on this 2 hour podcast.

Dr. Steven Quay is featured on NewsNation to discuss a new medical breakthrough cancer pill which early research suggests it destroys all solid tumors. Dr. Quay says it’s a “highly significant finding”.